---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-09-04T23:24:00.730187'
end_time: '2026-09-04T23:37:15.377869'
duration_seconds: 794.65
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Autosomal Dominant Cutis Laxa 1
  mondo_id: ''
  category: Mendelian
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    max_embedded_images: 8
citation_count: 30
reference_validation:
  total_references: 8
  verified: 8
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 8
  on_topic: 2
  validator_version: 0.2.1
term_validation:
  total_terms: 0
  verified: 0
  not_found: 0
  obsolete: 0
  unverifiable: 0
  confabulation_rate: 0.0
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 1
artifact_sources:
  edison_answer_artifacts: 1
artifacts:
- filename: artifact-00.md
  path: Autosomal_Dominant_Cutis_Laxa_1-deep-research-falcon_artifacts/artifact-00.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-00
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Autosomal Dominant Cutis Laxa 1
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Autosomal Dominant Cutis Laxa 1** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Autosomal Dominant Cutis Laxa 1
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Autosomal Dominant Cutis Laxa 1** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


# Autosomal Dominant Cutis Laxa 1: Disease Characteristics Report

## Executive summary and scope

Autosomal dominant cutis laxa 1 (ADCL1) is an exceptionally rare, germline **ELN-related elastinopathy**. Its defining manifestation is congenital or early-onset loose, redundant, poorly elastic skin, but it is a systemic disorder because aortic-root dilatation, valvular disease, pulmonary emphysema, and hernias can occur. The best quantitative evidence remains a 2013 cohort of only 20 clinically evaluated patients; accordingly, frequencies below are estimates from selected families rather than population-level rates. Recent ADCL1-specific research in 2023–2024 was extremely limited, and contemporary work has not displaced the mechanistic model established by human fibroblast, ultrastructural, and transgenic-mouse studies. (hadjrabia2013twentypatientsincluding pages 1-2, callewaert2011newinsightsinto pages 10-12)

A compact knowledge-base representation is provided here, followed by detailed interpretation.

| Domain | Evidence-backed findings | Quantitative data / representative variants | Suggested ontology terms |
|---|---|---|---|
| Disease identity | **Autosomal dominant cutis laxa 1 (ADCL1)** is an ELN-related systemic elastinopathy characterized by loose, inelastic skin and variable cardiovascular and pulmonary disease. Evidence is primarily aggregated from cohorts, families, and case reports rather than EHR-derived datasets. **OMIM: 123700**; MONDO, Orphanet, MeSH, and disease-specific ICD identifiers require direct database verification. (hadjrabia2013twentypatientsincluding pages 1-2, hadjrabia2013twentypatientsincluding pages 6-7, lasio2018elastindrivengeneticdiseases pages 2-4) | Largest cited cohort: 20 clinically evaluated individuals, ages 1–84 years. (hadjrabia2013twentypatientsincluding pages 1-2) | Autosomal dominant cutis laxa; cutis laxa; elastinopathy; MONDO term to verify |
| Disease boundary | ADCL1 is principally caused by **ELN** variants. It must not be conflated with **FBLN5-related cutis laxa**, which is predominantly autosomal recessive cutis laxa type 1A; FBLN5 is not the established primary cause of ELN-related ADCL1. (hadjrabia2013twentypatientsincluding pages 5-6, callewaert2011newinsightsinto pages 1-2, hadjrabia2013twentypatientsincluding pages 6-7) | ELN gene OMIM: **130160**. | ELN; elastic-fiber disorder; autosomal recessive cutis laxa type 1A |
| Cutaneous phenotype | Congenital or early-childhood loose, redundant, poorly elastic skin is defining. Disease may be localized or generalized and can become less conspicuous with age. Dermal elastic fibers are reduced, fragmented, branching, or disorganized. (hadjrabia2013twentypatientsincluding pages 1-2, kun2022congenitalcutislaxa pages 2-4, callewaert2011newinsightsinto pages 1-2) | Skin laxity **100%**; generalized/extensive involvement **75%**; localized redundancy **25%** in the 20-person cohort. (hadjrabia2013twentypatientsincluding pages 1-2) | HPO: Cutis laxa; redundant skin; generalized skin laxity; abnormality of dermal elastic fibers |
| Craniofacial phenotype | Features include a long or coarse prematurely aged face, large pliant ears, long philtrum, beaked nose, ptosis, and blepharochalasis. (hadjrabia2013twentypatientsincluding pages 5-6, kun2022congenitalcutislaxa pages 1-2) | Facial gestalt reported in **100%** in one cohort analysis; the long-face, large-ear, long-philtrum, and beaked-nose combination occurred in approximately **70%**. (hadjrabia2013twentypatientsincluding pages 5-6, hadjrabia2013twentypatientsincluding pages 1-2) | HPO: Long face; long philtrum; beaked nose; large ears; ptosis; blepharochalasis; prematurely aged appearance |
| Hernias | Inguinal and less frequently umbilical hernias reflect impaired connective-tissue elasticity. (graul‐neumann2008highlyvariablecutis pages 1-2, callewaert2011newinsightsinto pages 6-7) | Inguinal hernia approximately **50–51%**. (hadjrabia2013twentypatientsincluding pages 5-6, hadjrabia2013twentypatientsincluding pages 1-2) | HPO: Inguinal hernia; umbilical hernia |
| Cardiovascular phenotype | Aortic-root dilatation is a major complication and may progress during childhood or adolescence. Associated abnormalities include bicuspid aortic valve, mitral-valve prolapse, and other valve defects. (callewaert2011newinsightsinto pages 10-12, callewaert2011newinsightsinto pages 6-7) | Aortic-root dilatation **55–57%**; other valve anomalies **38%**; bicuspid aortic valve **5%**. One patient's aortic root progressed from 41 to 45 mm by age 17. (hadjrabia2013twentypatientsincluding pages 5-6, callewaert2011newinsightsinto pages 6-7) | HPO: Aortic-root dilatation; ascending-aortic dilatation; bicuspid aortic valve; mitral-valve prolapse |
| Pulmonary phenotype | Pulmonary emphysema and obstructive lung disease can be early and severe. Rare congenital presentations include recurrent pneumothorax and prolonged respiratory support. (graul‐neumann2008highlyvariablecutis pages 1-2, callewaert2011newinsightsinto pages 6-7) | Emphysema **35–37%**. One child had FEV1/FVC **42.9%** and residual volume **209%** at age 12. (hadjrabia2013twentypatientsincluding pages 1-2, callewaert2011newinsightsinto pages 6-7) | HPO: Pulmonary emphysema; obstructive lung disease; pneumothorax; dyspnea |
| Causal variants | Causal variants are heterozygous germline **ELN** alterations, most commonly 3-prime frameshifts in exons 30–34 that produce stable tropoelastin with an abnormal extended C terminus. Splice variants may generate the same downstream frameshift. (hadjrabia2013twentypatientsincluding pages 5-6, callewaert2011newinsightsinto pages 1-2, hadjrabia2013twentypatientsincluding pages 1-2, lasio2018elastindrivengeneticdiseases pages 4-6) | Representative variants: **c.2262delA** hotspot, c.2365delC, c.2189delG, c.2142delG, c.2296_2299dupGCAG, c.2333delC, c.2137delG, c.2124del25, c.2323delG (p.Ala775fs), and c.1985delG (p.Gly662Alafs*25). (hadjrabia2013twentypatientsincluding pages 5-6, callewaert2011newinsightsinto pages 1-2, kun2022congenitalcutislaxa pages 2-4, okuneva2019anovelelastin pages 2-4) | ELN; germline pathogenic variant; frameshift variant; splice-altering variant; abnormal protein C terminus |
| Allele rarity | Pathogenic alleles are very rare or absent from population reference datasets. Classification should follow ACMG/AMP criteria using phenotype, segregation, population frequency, predicted C-terminal extension, and functional evidence. (kun2022congenitalcutislaxa pages 2-4, okuneva2019anovelelastin pages 2-4) | c.2323delG was absent from ExAC (**60,706** individuals), 1000 Genomes (**2,535**), and a local database (**2,000**); cohort variants were absent from 100 controls. (okuneva2019anovelelastin pages 2-4, hadjrabia2013twentypatientsincluding pages 2-4) | Pathogenic variant; likely pathogenic variant; variant of uncertain significance; ACMG/AMP classification |
| Molecular mechanism | Mutant tropoelastin has increased self-association and globule formation, impaired binding to fibrillin-1 and fibulin-5-containing microfibrils, and reduced deposition of mature insoluble elastin. Incorporation of abnormal protein disrupts elastic-fiber assembly, supporting a **dominant-negative** mechanism with possible toxic gain of function. (callewaert2011newinsightsinto pages 10-12, lasio2018elastindrivengeneticdiseases pages 4-6) | Representative frameshifts generated predicted extensions of approximately **49, 53, or 86 amino acids**. (callewaert2011newinsightsinto pages 10-12) | GO: Elastic-fiber assembly; extracellular-matrix organization; protein self-association; tropoelastin coacervation |
| Downstream biology | Allele-dependent misfolding can cause endoplasmic-reticulum stress, unfolded-protein-response activation, and apoptosis. Increased pSMAD2 suggests enhanced TGF-beta signaling, hypothesized rather than conclusively proven to contribute to emphysema and aortic-root dilation. (callewaert2011newinsightsinto pages 10-12) | Exon 30 alleles increased BiP, phosphorylated eIF2-alpha, and caspase-3; exon 32 alleles produced less extensive UPR activation. (callewaert2011newinsightsinto pages 10-12) | GO: Response to endoplasmic-reticulum stress; unfolded protein response; apoptotic process; TGF-beta receptor signaling; SMAD signal transduction |
| Biological modifiers | Alternative ELN splicing and tissue-specific mutant-protein incorporation modify severity. Exon 32 skipping may reduce mutant burden, but exon-specific genotype–phenotype associations remain provisional. (hadjrabia2013twentypatientsincluding pages 5-6, callewaert2011newinsightsinto pages 7-9, lasio2018elastindrivengeneticdiseases pages 4-6) | Exon 32 was absent from approximately **70% of control transcripts** in one study. (callewaert2011newinsightsinto pages 7-9) | GO: Alternative mRNA splicing; nonsense-mediated mRNA decay; tissue-specific gene expression |
| Anatomy and cells | Elastic-fiber-rich skin, aortic wall, cardiac valves, lung parenchyma, and hernia-prone connective tissues are affected. Relevant cells include dermal fibroblasts, vascular smooth-muscle cells, and pulmonary fibroblasts; compartments include the ER, extracellular matrix, microfibrils, and elastic fibers. (akcay2020consequencesofelastin pages 1-3, callewaert2011newinsightsinto pages 10-12) | Elastin constitutes approximately **90%** of mature elastic fibers by mass in the cited review. (akcay2020consequencesofelastin pages 1-3) | CL: Fibroblast; vascular smooth-muscle cell; pulmonary fibroblast. UBERON: Skin; dermis; aortic wall; lung; cardiac valve. GO-CC: Endoplasmic reticulum; extracellular matrix; elastic fiber |
| Inheritance | Inheritance is autosomal dominant; familial vertical transmission and de novo variants are documented. Cutaneous penetrance appears high, while systemic manifestations show marked variable expressivity. Anticipation, founder effects, and germline mosaicism are not established. (callewaert2011newinsightsinto pages 1-2, hadjrabia2013twentypatientsincluding pages 2-4, hadjrabia2013twentypatientsincluding pages 1-2) | Phenotype transmitted in **20/22 meioses**; five probands in one study had de novo variants. (callewaert2011newinsightsinto pages 1-2, hadjrabia2013twentypatientsincluding pages 1-2) | Autosomal dominant inheritance; variable expressivity; de novo variant; penetrance |
| Epidemiology | ADCL1 is exceptionally rare. No reliable population prevalence, incidence, carrier frequency, sex ratio, founder effect, or geographic gradient was identified; evidence consists mainly of small families and case reports. | Largest cited cohort had **20 clinically evaluated patients** from six families plus one sporadic case. (hadjrabia2013twentypatientsincluding pages 1-2) | Rare genetic disease; orphan disease |
| Diagnosis | Diagnosis combines congenital or early skin laxity, characteristic facial appearance, family history, systemic assessment, and molecular confirmation. Testing may begin with ELN exons 30–34 but should expand to full ELN analysis or a connective-tissue/cutis-laxa panel; WES or WGS is useful when targeted testing is negative. Skin biopsy is supportive but not required and may correlate poorly with severity. (graul‐neumann2008highlyvariablecutis pages 1-2, kun2022congenitalcutislaxa pages 2-4, hadjrabia2013twentypatientsincluding pages 5-6, okuneva2019anovelelastin pages 2-4) | Histology may show absent, markedly reduced, broken, or disorganized dermal elastic fibers; a severe neonatal case showed only mild rarefaction. (graul‐neumann2008highlyvariablecutis pages 1-2, kun2022congenitalcutislaxa pages 2-4) | ELN sequencing; multigene panel; whole-exome sequencing; whole-genome sequencing; skin biopsy |
| Differential diagnosis | Differential diagnoses include FBLN5-, EFEMP2/FBLN4-, LTBP4-, ATP6V0A2-, and PYCR1-related recessive cutis laxa, Ehlers–Danlos syndromes, arterial-tortuosity syndrome, occipital-horn syndrome, acquired cutis laxa, and progeroid disorders. ELN haploinsufficiency more typically causes supravalvular aortic stenosis, while 7q11.23 deletion causes Williams–Beuren syndrome. (callewaert2011newinsightsinto pages 1-2, akcay2020consequencesofelastinb pages 1-3, kun2022congenitalcutislaxa pages 2-4, hadjrabia2013twentypatientsincluding pages 5-6) | Severe neurologic, ocular, skeletal, gastrointestinal, or generalized arterial disease should prompt reconsideration of the subtype. (callewaert2011newinsightsinto pages 1-2, hadjrabia2013twentypatientsincluding pages 6-7) | Ehlers–Danlos syndrome; arterial-tortuosity syndrome; supravalvular aortic stenosis; Williams syndrome; acquired cutis laxa |
| Surveillance | Baseline and lifelong cardiovascular and pulmonary evaluation are recommended. Assessments include echocardiography of the aortic root, ascending aorta, and valves; cross-sectional angiography when indicated; respiratory review; spirometry; lung volumes; and chest CT when clinically justified. Exact intervals are not standardized and require specialist individualization. (hadjrabia2013twentypatientsincluding pages 1-2, callewaert2011newinsightsinto pages 6-7) | Progressive childhood aortic disease and severe pediatric COPD have been documented. (callewaert2011newinsightsinto pages 6-7) | Echocardiography; magnetic-resonance angiography; computed tomography; spirometry; pulmonary-function testing |
| Treatment | No approved disease-modifying drug, gene therapy, RNA therapy, or genotype-directed treatment exists. Care is supportive and complication-specific. Aortic intervention should use individualized aneurysm risk assessment; emphysema is treated according to respiratory standards. Losartan has been proposed mechanistically but lacks ADCL1-specific efficacy evidence. (hadjrabia2013twentypatientsincluding pages 5-6, callewaert2011newinsightsinto pages 6-7) | No disease-specific response-rate data or randomized trials were identified. | NCIT labels: Supportive care; cardiovascular surgery; hernia repair; pulmonary rehabilitation; genetic counseling |
| Cutaneous surgery | Rhytidectomy or excision can improve appearance temporarily, but recurrence is common because the underlying elastic-fiber defect persists. Hernias may be repaired when clinically indicated. (kun2022congenitalcutislaxa pages 2-4, kun2022congenitalcutislaxa pages 1-2, callewaert2011newinsightsinto pages 6-7) | Review of **7 surgical patients** found recurrence within months in **5**; two required more than two operations. One recent case had no recurrence at five months. (kun2022congenitalcutislaxa pages 2-4) | NCIT labels: Rhytidectomy; reconstructive surgery; hernia repair |
| Prognosis and quality of life | Prognosis is highly variable. Skin laxity may improve with age, but aortic disease and emphysema can progress and dominate morbidity. Published survival, mortality, disability, and validated quality-of-life statistics are unavailable. Cosmetic distress, exertional dyspnea, recurrent surgery, and surveillance burden are plausible major impacts but are not quantified by disease-specific instruments. (kun2022congenitalcutislaxa pages 1-2, hadjrabia2013twentypatientsincluding pages 1-2, callewaert2011newinsightsinto pages 6-7) | Documented patient ages extend to **84 years**, but this is not a life-expectancy estimate. (hadjrabia2013twentypatientsincluding pages 1-2) | Quality of life; chronic disease; exercise intolerance; facial appearance concern |
| Models | Human dermal fibroblasts and skin-equivalent systems reproduce abnormal tropoelastin deposition, ER stress, and elastic-fiber disorganization. A humanized transgenic mouse carrying an ADCL ELN frameshift incorporated mutant elastin into skin and lung fibers, developing adverse tissue effects and emphysema; mutant incorporation into aortic elastin was comparatively low, demonstrating tissue-specific assembly. (callewaert2011newinsightsinto pages 10-12) | Model findings include intracellular retention, apoptosis, emphysema, reduced lung stiffness, increased stretch, and increased TGF-beta signaling. (callewaert2011newinsightsinto pages 10-12) | Model organism: Mus musculus; transgenic model; humanized mouse; fibroblast culture; skin-equivalent model |
| Environmental and protective factors | ADCL1 is a monogenic disorder; no environmental cause or proven protective genetic, dietary, lifestyle, infectious, or occupational factor was identified. Avoidance of smoking and pulmonary irritants is clinically prudent for emphysema risk but is not proven to modify ADCL1 penetrance. | No ADCL1-specific gene–environment interaction statistics are available. | Tobacco-smoke exposure; air pollution exposure; environmental modifier |
| Evidence gaps | Major gaps include contemporary natural-history cohorts, 2023–2024 ADCL1-specific studies, validated prevalence, standardized surveillance intervals, prospective surgical outcomes, quality-of-life measures, prognostic biomarkers, modifier genes, epigenomics, single-cell or spatial profiling, and disease-modifying trials. | Available quantitative estimates rely heavily on a 20-person cohort and individual case reports. (hadjrabia2013twentypatientsincluding pages 1-2, hadjrabia2013twentypatientsincluding pages 5-6) | Natural history study; patient registry; multi-omics study; clinical trial |


*Table: Compact evidence table for ELN-related autosomal dominant cutis laxa 1, covering phenotype frequencies, variants, mechanism, diagnosis, surveillance, treatment, and evidence gaps. It explicitly distinguishes ADCL1 from predominantly recessive FBLN5-related cutis laxa.*

## 1. Disease information

**Definition.** ADCL1 is a Mendelian connective-tissue disorder in which heterozygous pathogenic variants—usually frameshifts near the 3′ end of **ELN**—produce abnormal tropoelastin and defective elastic fibers. Unlike ordinary skin hyperextensibility, cutis laxa denotes skin that is loose, hangs in folds, and returns slowly after stretching. Internal elastic-fiber-rich organs may also be affected. (callewaert2011newinsightsinto pages 1-2, hadjrabia2013twentypatientsincluding pages 1-2, lasio2018elastindrivengeneticdiseases pages 4-6)

**Identifiers and nomenclature.** The securely supported identifier is **OMIM/MIM 123700**. Common names are *autosomal dominant cutis laxa*, *autosomal dominant cutis laxa type 1*, *ADCL*, *ADCL1*, *ELN-related cutis laxa*, and *dominant cutis laxa*. ELN itself is OMIM 130160. A subtype-specific MONDO identifier could not be verified from the retrieved evidence; similarly, Orphanet, MeSH, ICD-10, and ICD-11 appear to classify cutis laxa more broadly rather than providing a reliably verified ADCL1-specific code. These fields should therefore be resolved directly against current ontology releases rather than inferred. (hadjrabia2013twentypatientsincluding pages 1-2, lasio2018elastindrivengeneticdiseases pages 2-4)

**Critical disease boundary.** ADCL1 should not be mislabeled as FBLN5-related disease. Classical ADCL1 is **ELN-related**, whereas biallelic **FBLN5** variants predominantly cause autosomal-recessive cutis laxa type 1A. Reports suggesting dominant FBLN5 cutis laxa have not established FBLN5 as the routine cause of ADCL1. (hadjrabia2013twentypatientsincluding pages 5-6, callewaert2011newinsightsinto pages 1-2, hadjrabia2013twentypatientsincluding pages 6-7)

**Evidence provenance.** Available information is aggregated from disease-level resources, multigenerational pedigrees, small cohorts, case reports, patient-derived fibroblasts, biopsies, and engineered mice. It is not based on a representative EHR population.

## 2. Etiology, risk, and protective factors

### Causal factors

ADCL1 is caused by a heterozygous constitutional **ELN** pathogenic variant. Most established alleles are frameshifts in exons 30–34 that escape complete nonsense-mediated decay and encode tropoelastin with a missense-altered, extended C terminus. Splice-altering variants can converge on the same abnormal reading frame. This differs from ELN haploinsufficiency, which more characteristically causes supravalvular aortic stenosis, and from a 7q11.23 deletion including ELN, which causes Williams–Beuren syndrome. (akcay2020consequencesofelastinb pages 1-3, hadjrabia2013twentypatientsincluding pages 1-2, lasio2018elastindrivengeneticdiseases pages 4-6)

### Genetic risk and modifiers

A pathogenic ELN allele is the primary risk factor; an affected heterozygous parent confers a theoretical **50% risk per pregnancy**. Both vertical transmission and de novo occurrence are documented. Alternative ELN splicing is a demonstrated biological modifier: exon 32 was absent from about 70% of control transcripts in one study, potentially reducing the burden of variants located in that exon. Tissue-specific incorporation of mutant protein also modifies organ involvement. Firm modifier genes, founder alleles, or polygenic risk scores have not been established. (callewaert2011newinsightsinto pages 1-2, callewaert2011newinsightsinto pages 7-9, lasio2018elastindrivengeneticdiseases pages 4-6)

### Environmental and protective factors

No environmental, infectious, dietary, occupational, or lifestyle exposure causes inherited ADCL1, and no protective allele or intervention has been demonstrated. Avoiding tobacco smoke and inhaled pollutants is prudent because emphysema is an important complication, but this is extrapolated respiratory-risk reduction—not proof of an ADCL1-specific gene–environment interaction. Alpha-1-antitrypsin deficiency was excluded in two severely affected patients, indicating that their emphysema was not explained by that common genetic risk factor. (callewaert2011newinsightsinto pages 7-9)

## 3. Phenotypes

The strongest frequency estimates come from 20 clinically evaluated individuals aged 1–84 years. Because ascertainment was syndromic and familial, confidence intervals and generalizability are limited. (hadjrabia2013twentypatientsincluding pages 1-2)

* **Cutis laxa—clinical sign/physical manifestation:** present in **100%**; approximately 75% had extensive/generalized laxity and 25% localized redundancy involving the face, neck, axillae, or groin. Onset is usually congenital or in infancy. Severity ranges from mild regional redundancy to severe neonatal disease; skin conspicuousness may lessen with age. Suggested HPO labels: *Cutis laxa*, *redundant skin*, *generalized skin laxity*, and *abnormality of dermal elastic fibers*. (hadjrabia2013twentypatientsincluding pages 1-2, kun2022congenitalcutislaxa pages 2-4)
* **Characteristic face—physical manifestation:** long or coarse prematurely aged face, large pliant ears, long philtrum, beaked nose, ptosis, and blepharochalasis. Facial gestalt was reported in all patients in one analysis, while the long-face/large-ear/long-philtrum/beaked-nose constellation occurred in about **70%**. Suggested HPO labels: *Long face*, *long philtrum*, *beaked nose*, *large ears*, *ptosis*, *blepharochalasis*, and *prematurely aged appearance*. (hadjrabia2013twentypatientsincluding pages 5-6, hadjrabia2013twentypatientsincluding pages 1-2)
* **Hernia—clinical sign:** inguinal hernia occurred in approximately **50–51%**; umbilical hernia is also reported. Hernias can arise in infancy and recur because the underlying matrix defect persists. Suggested HPO: *Inguinal hernia* and *umbilical hernia*. (hadjrabia2013twentypatientsincluding pages 5-6, graul‐neumann2008highlyvariablecutis pages 1-2, callewaert2011newinsightsinto pages 6-7)
* **Aortic disease—imaging/clinical sign:** aortic-root dilatation occurred in **55–57%** and may progress during childhood or adolescence. In one adolescent, the root increased from 41 mm to 45 mm by age 17. Suggested HPO: *Aortic root dilatation* and *ascending aortic dilatation*. (hadjrabia2013twentypatientsincluding pages 5-6, callewaert2011newinsightsinto pages 6-7)
* **Valvular disease—clinical/imaging sign:** other valve anomalies were reported in **38%**, with bicuspid aortic valve in **5%**; mitral-valve prolapse also occurs. Bicuspid valve may accompany both root and ascending-aortic enlargement. Suggested HPO: *Bicuspid aortic valve* and *mitral valve prolapse*. (hadjrabia2013twentypatientsincluding pages 5-6, callewaert2011newinsightsinto pages 10-12)
* **Pulmonary emphysema/obstruction—clinical and functional abnormality:** emphysema occurred in **35–37%** and can be severe in childhood. One 12-year-old had FEV1/FVC 42.9% and residual volume 209%. A severe congenital case had repeated pneumothoraces and required respiratory support through day 69. Suggested HPO: *Pulmonary emphysema*, *obstructive lung disease*, *pneumothorax*, and *dyspnea*. (hadjrabia2013twentypatientsincluding pages 1-2, graul‐neumann2008highlyvariablecutis pages 1-2, callewaert2011newinsightsinto pages 6-7)
* **Additional variable findings:** joint hypermobility, vocal-cord laxity/hoarse voice, diaphragmatic eventration, gastrointestinal or genitourinary diverticula, and feeding difficulty have been reported, but reliable ADCL1-specific frequencies are unavailable. (hadjrabia2013twentypatientsincluding pages 6-7, graul‐neumann2008highlyvariablecutis pages 1-2, callewaert2011newinsightsinto pages 6-7)

Formal EQ-5D, SF-36, PROMIS, disability, or behavioral data were not found. Cosmetic distress, exertional limitation, repeated surgery, and lifelong cardiopulmonary surveillance are clinically plausible burdens but remain unquantified.

## 4. Genetic and molecular information

**Causal gene.** **ELN**, encoding tropoelastin/elastin, lies in the 7q11 region. The retrieved literature describes ELN as a 34-exon gene spanning approximately 45 kb and elastin as the major mass component of mature elastic fibers. Exact current HGNC and genomic-transcript identifiers should be taken from HGNC/NCBI rather than assigned from the retrieved articles. (akcay2020consequencesofelastin pages 1-3)

**Representative pathogenic variants.** Reported heterozygous germline alleles include c.2262delA—a recurrent exon-32 hotspot—c.2365delC, c.2189delG, c.2142delG, c.2296_2299dupGCAG, c.2333delC, c.2137delG, c.2124del25, c.2323delG (p.Ala775fs), and c.1985delG (p.Gly662Alafs*25). Historical transcript differences can alter residue numbering, so clinical reinterpretation should normalize every allele to a current MANE transcript. (hadjrabia2013twentypatientsincluding pages 5-6, callewaert2011newinsightsinto pages 1-2, kun2022congenitalcutislaxa pages 2-4, okuneva2019anovelelastin pages 2-4)

**Variant classification and population frequency.** Variants producing the characteristic terminal frameshift may be pathogenic or likely pathogenic under ACMG/AMP criteria when supported by phenotype, segregation/de novo status, extreme rarity, and functional evidence. A 2019 c.2323delG allele was absent from ExAC's 60,706 individuals, 1000 Genomes' 2,535 individuals, and a 2,000-person local database; variants from another cohort were absent from 100 controls. These observations support rarity but are not allele-frequency estimates for ADCL1 overall. Missense or noncanonical splice variants require careful assessment; a VUS should not be used for predictive testing without further evidence. (okuneva2019anovelelastin pages 2-4, hadjrabia2013twentypatientsincluding pages 2-4)

**Origin and consequences.** Established variants are germline, not somatic. The dominant mechanism is best described as **dominant-negative with possible toxic gain of function**, rather than simple loss of function: stable mutant tropoelastin is secreted or retained, self-associates abnormally, and interferes with extracellular elastic-fiber assembly. Predicted abnormal C-terminal extensions of approximately 49, 53, or 86 residues were analyzed experimentally. (callewaert2011newinsightsinto pages 10-12, akcay2020consequencesofelastinb pages 1-3, lasio2018elastindrivengeneticdiseases pages 4-6)

No ADCL1-specific DNA-methylation signature, chromatin abnormality, recurrent CNV, aneuploidy, translocation, validated modifier gene, or somatic mosaic mechanism was identified. Large 7q11.23 deletions belong to the Williams–Beuren differential rather than typical ADCL1.

## 5. Environmental information

No toxin, radiation exposure, pollution source, occupation, diet, alcohol exposure, or infectious agent is established as causal or triggering. Standard avoidance of smoking, vaping, and avoidable pulmonary irritants is reasonable tertiary prevention for any patient at risk of emphysema, but no study quantified its effect in ADCL1. There is no zoonotic or transmissible component.

## 6. Mechanism and pathophysiology

### Ordered causal chain

1. A heterozygous 3′ **ELN** frameshift or functionally equivalent splice defect **leads to** stable mutant transcripts encoding tropoelastin with an abnormal extended C terminus. (hadjrabia2013twentypatientsincluding pages 1-2, lasio2018elastindrivengeneticdiseases pages 4-6)
2. The altered C-terminal assembly domain **leads to** increased self-association, lower coacervation temperature, and abnormal elastin globules. (callewaert2011newinsightsinto pages 10-12)
3. Abnormal tropoelastin binding to fibrillin-1/fibulin-5 microfibrils **results in** poor elastin–microfibril integration and reduced mature insoluble elastin deposition. (callewaert2011newinsightsinto pages 10-12, merla2012supravalvularaorticstenosis pages 2-3)
4. Incorporation of mutant protein into fibers **leads to** a dominant-negative disruption of elastic-fiber architecture; intracellular retention can additionally **result in** ER stress, unfolded-protein-response activation, and apoptosis in an allele-dependent manner. (callewaert2011newinsightsinto pages 1-2, callewaert2011newinsightsinto pages 10-12)
5. Reduced and fragmented elastic fibers **result in** loss of recoil in dermis, aortic wall, valves, lung parenchyma, and hernia-prone connective tissue. (callewaert2011newinsightsinto pages 1-2, hadjrabia2013twentypatientsincluding pages 1-2)
6. Loss of dermal recoil **causes** loose redundant skin and the characteristic aged facial appearance; loss of connective-tissue support **causes** hernias and possibly diverticula. (hadjrabia2013twentypatientsincluding pages 6-7, hadjrabia2013twentypatientsincluding pages 1-2)
7. Loss of pulmonary elastic recoil **causes** air-space enlargement, obstruction, emphysema, and occasionally pneumothorax. (graul‐neumann2008highlyvariablecutis pages 1-2, callewaert2011newinsightsinto pages 6-7)
8. Loss of arterial/valvular matrix integrity **leads to** aortic-root dilatation and valve abnormalities. Increased pSMAD2/TGF-β signaling may amplify remodeling, but this downstream contribution remains mechanistically inferred rather than proven as a treatment-responsive driver in humans. (callewaert2011newinsightsinto pages 10-12)
9. **Modifier branch:** alternative exon splicing and tissue-specific mutant-protein incorporation **alter** mutant dosage and therefore organ severity; this explains some inter- and intrafamilial variability. (callewaert2011newinsightsinto pages 7-9, lasio2018elastindrivengeneticdiseases pages 4-6)

**Cells and processes.** Dermal fibroblasts are directly supported by patient-cell studies; vascular smooth-muscle cells and pulmonary matrix-producing cells are biologically relevant but less directly profiled in human ADCL1. Suggested GO biological-process labels include *elastic fiber assembly*, *extracellular matrix organization*, *protein folding*, *response to endoplasmic-reticulum stress*, *unfolded protein response*, *apoptotic process*, *TGF-beta receptor signaling*, and *alternative mRNA splicing*. Suggested Cell Ontology labels are *fibroblast*, *dermal fibroblast*, *vascular smooth-muscle cell*, and *pulmonary fibroblast*.

**Molecular profiling.** Human biopsy electron microscopy demonstrated reduced, fragmented, branched, or disorganized elastic fibers and abnormal globules. Patient fibroblasts showed defective deposition, reduced insoluble elastin, allele-specific BiP, phosphorylated eIF2α and caspase-3 responses, and increased pSMAD2. These are targeted cellular/protein assays, not unbiased transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial, or multi-omic profiles. No ADCL1-specific omics signature or CRISPR screen was found. (callewaert2011newinsightsinto pages 1-2, callewaert2011newinsightsinto pages 7-9, callewaert2011newinsightsinto pages 10-12)

A useful direct abstract statement from the humanized-mouse study is: **“Mutant transcripts incorporate into elastic fibers of skin and lung with adverse effects but not aorta.”** This supports tissue-specific assembly as a biological modifier rather than assuming equal effects in all elastic tissues.

## 7. Anatomical structures affected

* **Primary:** skin/dermis, particularly face, neck, axillae, groin, and generalized integument; suggested UBERON labels: *skin of body*, *dermis*, *skin of face*.
* **Cardiovascular:** aortic root, ascending aorta, arterial elastic lamellae, aortic and mitral valves; suggested UBERON: *aortic root*, *ascending aorta*, *aortic valve*, *mitral valve*.
* **Respiratory:** lung parenchyma/alveolar elastic matrix and, variably, vocal cords; suggested UBERON: *lung*, *pulmonary alveolus*, *vocal fold*.
* **Supportive connective tissues:** inguinal and umbilical regions, diaphragm, and hollow-viscus walls.
* **Subcellular/extracellular:** ER, secretory pathway, extracellular matrix, microfibrils, and elastic fibers; suggested GO cellular components: *endoplasmic reticulum*, *extracellular matrix*, and *elastic fiber*.

Disease is generally bilateral/generalized rather than lateralized. Regional skin severity can nevertheless be asymmetric after growth or surgery.

## 8. Temporal development

Onset is usually congenital or during infancy and is chronic/lifelong. Skin folds may become less prominent with growth, but this is not molecular remission. Cardiovascular and pulmonary complications can emerge or progress during childhood, adolescence, or adulthood even when the skin phenotype appears mild. Severe neonatal respiratory presentations are possible but uncommon. (graul‐neumann2008highlyvariablecutis pages 1-2, kun2022congenitalcutislaxa pages 2-4, hadjrabia2013twentypatientsincluding pages 1-2, callewaert2011newinsightsinto pages 6-7)

There is no validated staging system. A practical course model is: (1) congenital/early cutaneous recognition; (2) ascertainment of hernia and baseline cardiopulmonary involvement; (3) longitudinal monitoring for aortic enlargement, valve disease, and airflow obstruction; and (4) complication-directed intervention. No spontaneous genetic remission occurs. Critical opportunities are early molecular diagnosis, baseline cardiovascular/pulmonary assessment, and continued surveillance through growth and pregnancy planning.

## 9. Inheritance and population

Inheritance is autosomal dominant, with marked variable expressivity. Phenotypic transmission occurred in 20 of 22 observed meioses in the principal cohort, and five de novo variants were reported in another series. Cutaneous penetrance appears high in documented pedigrees, while penetrance of aortic and pulmonary complications is incomplete or age dependent. Genetic anticipation is not established. Germline mosaicism is theoretically possible after an apparently de novo case but was not demonstrated in the retrieved evidence. Consanguinity does not cause this dominant disorder, although it may complicate differential diagnosis with recessive cutis-laxa syndromes. (callewaert2011newinsightsinto pages 1-2, hadjrabia2013twentypatientsincluding pages 2-4, hadjrabia2013twentypatientsincluding pages 1-2)

No reliable incidence, prevalence per 100,000, carrier frequency, sex ratio, ethnic enrichment, founder effect, or geographic gradient is available. The largest cited cohort contained only 20 evaluated patients from six families plus one sporadic case. Both sexes and multiple geographic populations have been reported, without evidence of sex-linked risk. (hadjrabia2013twentypatientsincluding pages 1-2)

## 10. Diagnostics

### Clinical and laboratory evaluation

Diagnosis begins with congenital/early loose inelastic skin, characteristic facial morphology, hernias, and family history, followed by cardiovascular and respiratory assessment. Baseline evaluation should include echocardiography of the aortic root, ascending aorta, and valves; ECG as clinically indicated; spirometry and lung volumes; and chest CT or MR/CT angiography when symptoms or initial findings justify radiation/cross-sectional imaging. There is no validated circulating biomarker or enzyme assay. (hadjrabia2013twentypatientsincluding pages 5-6, callewaert2011newinsightsinto pages 6-7, hadjrabia2013twentypatientsincluding pages 1-2)

Skin biopsy with an elastic-fiber stain or electron microscopy is supportive: fibers may be absent, reduced, fragmented, branched, or poorly deposited. It is not definitive, because a severely affected neonate showed only mild elastic-fiber rarefaction. (graul‐neumann2008highlyvariablecutis pages 1-2, kun2022congenitalcutislaxa pages 2-4, callewaert2011newinsightsinto pages 1-2)

### Genetic testing

1. Use an **ELN-inclusive cutis-laxa/connective-tissue panel** when the phenotype is recognizable but genetically heterogeneous.
2. Single-gene ELN sequencing may initially prioritize exons 30–34, but full coding/splice-region analysis is preferable because pathogenic splice variants can occur elsewhere.
3. Include deletion/duplication analysis where the assay does not detect CNVs.
4. Use WES or WGS when panel testing is negative, phenotype is atypical, or dual diagnoses are suspected; confirm clinically actionable variants by an orthogonal method and perform parental/segregation testing.
5. RNA studies from fibroblasts can resolve splice variants or transcript escape but are specialist functional tests, not routine first-line diagnostics. (graul‐neumann2008highlyvariablecutis pages 1-2, hadjrabia2013twentypatientsincluding pages 5-6, okuneva2019anovelelastin pages 2-4)

CMA, karyotyping, and FISH are not first-line tests for typical ADCL1 but may identify a 7q11.23 deletion in the Williams–Beuren differential. Mitochondrial-DNA and repeat-expansion testing are not applicable. No validated RNA-seq, proteomic, metabolomic, epigenomic, or liquid-biopsy diagnostic exists.

### Differential diagnosis

Consider FBLN5-, EFEMP2/FBLN4-, LTBP4-, ATP6V0A2-, PYCR1-, and other recessive cutis-laxa syndromes; arterial-tortuosity syndrome; occipital-horn syndrome; Ehlers–Danlos syndromes; acquired inflammatory cutis laxa; progeroid disorders; isolated ELN-related supravalvular aortic stenosis; and Williams–Beuren syndrome. Severe developmental, neurologic, ocular, skeletal, metabolic, gastrointestinal, or diffuse arterial abnormalities should trigger reassessment for another subtype. Ehlers–Danlos skin is typically hyperextensible and associated with tissue fragility/abnormal collagen, whereas cutis-laxa skin is redundant and returns slowly. (callewaert2011newinsightsinto pages 1-2, kun2022congenitalcutislaxa pages 2-4, hadjrabia2013twentypatientsincluding pages 5-6)

No population or newborn screening program exists. Once a familial pathogenic variant is known, targeted cascade testing is appropriate.

## 11. Outcome and prognosis

Prognosis is variable and primarily determined by aortic and pulmonary involvement rather than cutaneous severity. Skin appearance may improve, while aortic-root dilatation or emphysema progresses. Patients in the principal cohort ranged up to 84 years, but that observation is not a life-expectancy estimate. No valid 5-year/10-year survival, mortality rate, disability rate, or prognostic-biomarker model is available. (hadjrabia2013twentypatientsincluding pages 1-2, callewaert2011newinsightsinto pages 6-7)

Potential major morbidity includes progressive aneurysmal aortic disease, valve dysfunction, severe COPD/emphysema, pneumothorax, recurrent hernias, hoarseness, exercise limitation, and recurrent cosmetic laxity after surgery. Variant position and exon skipping may influence severity, but current cohorts are too small for dependable genotype-based prognosis. (hadjrabia2013twentypatientsincluding pages 5-6, callewaert2011newinsightsinto pages 7-9, lasio2018elastindrivengeneticdiseases pages 4-6)

## 12. Treatment and current applications

There is no approved therapy that corrects ELN or regenerates normal elastic fibers, and no ADCL1-specific gene, cell, RNA, CRISPR, targeted, or immunotherapy was identified. A ClinicalTrials.gov search found no relevant interventional ADCL1 trial; retrieved “skin laxity” trials addressed cosmetic/acquired laxity and should not be annotated as ADCL1 studies.

**Current real-world care** is multidisciplinary and complication directed:

* **Cardiovascular:** serial echocardiography, cross-sectional imaging when indicated, blood-pressure management, and referral to an inherited-aortopathy team. Aortic surgery must be individualized using diameter, growth rate, body size, valve anatomy, family history, pregnancy plans, and operative risk; ADCL1-specific thresholds have not been validated. Losartan has been proposed because of increased TGF-β signaling, but there is no ADCL1-specific efficacy trial. Suggested NCIT labels: *Echocardiography*, *antihypertensive therapy*, and *cardiovascular surgery*. (hadjrabia2013twentypatientsincluding pages 5-6)
* **Pulmonary:** smoking avoidance, vaccination according to routine respiratory guidance, bronchodilator/other COPD therapy when clinically indicated, pulmonary rehabilitation, prompt treatment of infections, and pneumothorax management. These are standard-care extrapolations, not genotype-specific treatments. Suggested NCIT: *Supportive care* and *pulmonary rehabilitation*.
* **Hernias:** repair when symptomatic or at risk of complications. Suggested NCIT: *Hernia repair*.
* **Cutaneous/cosmetic:** rhytidectomy or staged excision may temporarily improve appearance. Evidence is weak: among seven surgical patients summarized in a 2022 review, five had recurrence within months and two required more than two procedures; one recent patient remained recurrence-free at only five months. Suggested NCIT: *Rhytidectomy* and *reconstructive surgery*. (kun2022congenitalcutislaxa pages 2-4, kun2022congenitalcutislaxa pages 1-2)
* **Genetic counseling and psychosocial care:** explain recurrence risk, variable expressivity, and limitations of predicting systemic severity; offer appearance-related and chronic-disease support.

No disease-specific pharmacogenomic guidance, combination regimen, response rate, or adverse-event dataset exists.

## 13. Prevention

Primary prevention by lifestyle or vaccination is impossible for a constitutional pathogenic allele. Reproductive options after identifying the familial variant include preimplantation genetic testing, prenatal diagnosis, donor gametes, or natural conception with testing, guided by nondirective counseling. Predictive cascade testing of at-risk relatives is the principal secondary-prevention strategy because it enables cardiopulmonary surveillance before symptoms. Tertiary prevention includes blood-pressure control, avoidance of smoking and pulmonary irritants, respiratory vaccination under standard schedules, prompt hernia management, and specialist surveillance for aortic growth and lung disease. No public-health screening, prophylactic medication, or immunization specifically prevents ADCL1.

## 14. Other species and natural disease

The causal biology is evolutionarily conserved because elastin is essential to vertebrate elastic tissues. Nevertheless, no well-established, naturally occurring veterinary syndrome precisely homologous to human ELN-terminal-frameshift ADCL1 was identified in the retrieved evidence. Therefore, breed/VBO identifiers, natural incidence, veterinary burden, cross-species transmission, and zoonotic potential are not applicable or unavailable. Relevant experimental taxonomy is **Mus musculus** (NCBI Taxonomy 10090); the human taxon is **Homo sapiens** (9606).

## 15. Model organisms and experimental systems

**Patient-derived fibroblasts and skin biopsy** provide the most direct human mechanistic models. They reproduce abnormal tropoelastin coacervation and deposition, reduced insoluble elastin, microfibril-binding defects, allele-specific ER stress/apoptosis, and increased pSMAD2. Their limitation is that cultured dermal fibroblasts do not reproduce whole-organ mechanics or age-dependent aortic and pulmonary disease. (callewaert2011newinsightsinto pages 10-12)

**Humanized transgenic mice** carrying a human ADCL ELN frameshift incorporated mutant protein into skin and lung elastic fibers and developed adverse lung effects/emphysema. Mutant incorporation into aortic elastin was low, illustrating tissue-specific assembly. A related transgenic model showed intracellular retention, apoptosis, reduced lung stiffness, increased stretch, and increased TGF-β signaling. These mice are useful for elastogenesis, pulmonary mechanics, tissue-specific splicing, and proof-of-mechanism studies, but primate-specific ELN splicing and structural differences limit direct genotype–phenotype translation. (callewaert2011newinsightsinto pages 10-12)

By contrast, ELN-null mice die neonatally from vascular obstruction and ELN-heterozygous mice develop hypertension and altered arterial lamellae; these are valuable elastin-dosage models but do not reproduce the dominant-negative terminal-frameshift mechanism of ADCL1. (akcay2020consequencesofelastina pages 1-3)

## Recent developments, expert interpretation, and research priorities

No 2023–2024 primary study retrieved here materially revised ADCL1 natural history or treatment. The most recent directly relevant clinical report in the search space described severe coronary disease in a young adult with an intronic ELN variant, but full text was unavailable and it was therefore not used as evidence. A 2024 bioinformatic study nominated oxidative-stress/SOD3-correlated genes across rare disorders, including dominant cutis laxa, but this is computational hypothesis generation rather than an ADCL1 biomarker or therapeutic validation.

The authoritative interpretation remains that ADCL1 is not merely cosmetic: the 2013 cohort concluded that **“regular cardiovascular and pulmonary evaluations are imperative.”** The central translational gap is the absence of prospective registries linking normalized ELN variants, transcript processing, organ imaging, pulmonary function, pregnancy outcomes, and patient-reported quality of life. Priority research needs are an international natural-history registry; standardized aortic and pulmonary surveillance intervals; longitudinal pregnancy data; updated gnomAD-normalized variant curation; patient-specific iPSC/organoid systems; single-cell and spatial profiling of aortic, pulmonary, and dermal matrix-producing cells; and preclinical tests of allele-specific RNA suppression or correction.

## Evidence limitations and key references

The field relies heavily on small, nonrepresentative cohorts and older mechanistic studies. Percentages must not be interpreted as population prevalence, absence of reported findings is not proof of absence, and proposed TGF-β-directed treatment remains unvalidated.

Key accessible publications include:

1. Hadj-Rabia S, et al. **Twenty patients including 7 probands with autosomal dominant cutis laxa confirm clinical and molecular homogeneity.** *Orphanet Journal of Rare Diseases*. Published February 2013;8:36. DOI/URL: https://doi.org/10.1186/1750-1172-8-36. (hadjrabia2013twentypatientsincluding pages 1-2)
2. Callewaert B, et al. **New insights into the pathogenesis of autosomal-dominant cutis laxa with report of five ELN mutations.** *Human Mutation*. Published April 2011;32:445–455. DOI/URL: https://doi.org/10.1002/humu.21462. (callewaert2011newinsightsinto pages 1-2)
3. Sugitani H, et al. **Alternative splicing and tissue-specific elastin misassembly act as biological modifiers of human elastin gene frameshift mutations associated with dominant cutis laxa.** *Journal of Biological Chemistry*. Published June 2012;287:22055–22067. DOI/URL: https://doi.org/10.1074/jbc.M111.327940. (callewaert2011newinsightsinto pages 10-12)
4. Graul-Neumann LM, et al. **Highly variable cutis laxa resulting from a dominant splicing mutation of the elastin gene.** *American Journal of Medical Genetics Part A*. Published April 2008;146A:977–983. DOI/URL: https://doi.org/10.1002/ajmg.a.32242. (graul‐neumann2008highlyvariablecutis pages 1-2)
5. Okuneva EG, et al. **A novel elastin gene frameshift mutation in a Russian family with cutis laxa: a case report.** *BMC Dermatology*. Published January 2019. DOI/URL: https://doi.org/10.1186/s12895-019-0084-6. (okuneva2019anovelelastin pages 2-4)
6. Kun Y, et al. **Congenital Cutis Laxa: A Case Report and Literature Review.** *Frontiers in Surgery*. Published March 2022;9:814897. DOI/URL: https://doi.org/10.3389/fsurg.2022.814897. (kun2022congenitalcutislaxa pages 2-4)

PMIDs were not exposed in the retrieved full-text metadata and are therefore not supplied from memory; DOI links are provided to avoid introducing unverified identifiers.

References

1. (hadjrabia2013twentypatientsincluding pages 1-2): Smail Hadj-Rabia, Bert L Callewaert, Emmanuelle Bourrat, Marlies Kempers, Astrid S Plomp, Valerie Layet, Deborah Bartholdi, Marjolijn Renard, Julie De Backer, Fransiska Malfait, Olivier M Vanakker, Paul J Coucke, Anne M De Paepe, and Christine Bodemer. Twenty patients including 7 probands with autosomal dominant cutis laxa confirm clinical and molecular homogeneity. Orphanet Journal of Rare Diseases, 8:36-36, Feb 2013. URL: https://doi.org/10.1186/1750-1172-8-36, doi:10.1186/1750-1172-8-36. This article has 59 citations and is from a peer-reviewed journal.

2. (callewaert2011newinsightsinto pages 10-12): Bert Callewaert, Marjolijn Renard, Vishwanathan Hucthagowder, Beate Albrecht, Ingrid Hausser, Edward Blair, Cristina Dias, Alice Albino, Hiroshi Wachi, Fumiaki Sato, Robert P. Mecham, Bart Loeys, Paul J. Coucke, Anne De Paepe, and Zsolt Urban. New insights into the pathogenesis of autosomal‐dominant cutis laxa with report of five eln mutations. Human Mutation, 32:445-455, Apr 2011. URL: https://doi.org/10.1002/humu.21462, doi:10.1002/humu.21462. This article has 179 citations and is from a domain leading peer-reviewed journal.

3. (hadjrabia2013twentypatientsincluding pages 6-7): Smail Hadj-Rabia, Bert L Callewaert, Emmanuelle Bourrat, Marlies Kempers, Astrid S Plomp, Valerie Layet, Deborah Bartholdi, Marjolijn Renard, Julie De Backer, Fransiska Malfait, Olivier M Vanakker, Paul J Coucke, Anne M De Paepe, and Christine Bodemer. Twenty patients including 7 probands with autosomal dominant cutis laxa confirm clinical and molecular homogeneity. Orphanet Journal of Rare Diseases, 8:36-36, Feb 2013. URL: https://doi.org/10.1186/1750-1172-8-36, doi:10.1186/1750-1172-8-36. This article has 59 citations and is from a peer-reviewed journal.

4. (lasio2018elastindrivengeneticdiseases pages 2-4): Maria Laura Duque Lasio and Beth A. Kozel. Elastin-driven genetic diseases. Oct 2018. URL: https://doi.org/10.1016/j.matbio.2018.02.021, doi:10.1016/j.matbio.2018.02.021. This article has 122 citations and is from a domain leading peer-reviewed journal.

5. (hadjrabia2013twentypatientsincluding pages 5-6): Smail Hadj-Rabia, Bert L Callewaert, Emmanuelle Bourrat, Marlies Kempers, Astrid S Plomp, Valerie Layet, Deborah Bartholdi, Marjolijn Renard, Julie De Backer, Fransiska Malfait, Olivier M Vanakker, Paul J Coucke, Anne M De Paepe, and Christine Bodemer. Twenty patients including 7 probands with autosomal dominant cutis laxa confirm clinical and molecular homogeneity. Orphanet Journal of Rare Diseases, 8:36-36, Feb 2013. URL: https://doi.org/10.1186/1750-1172-8-36, doi:10.1186/1750-1172-8-36. This article has 59 citations and is from a peer-reviewed journal.

6. (callewaert2011newinsightsinto pages 1-2): Bert Callewaert, Marjolijn Renard, Vishwanathan Hucthagowder, Beate Albrecht, Ingrid Hausser, Edward Blair, Cristina Dias, Alice Albino, Hiroshi Wachi, Fumiaki Sato, Robert P. Mecham, Bart Loeys, Paul J. Coucke, Anne De Paepe, and Zsolt Urban. New insights into the pathogenesis of autosomal‐dominant cutis laxa with report of five eln mutations. Human Mutation, 32:445-455, Apr 2011. URL: https://doi.org/10.1002/humu.21462, doi:10.1002/humu.21462. This article has 179 citations and is from a domain leading peer-reviewed journal.

7. (kun2022congenitalcutislaxa pages 2-4): Yang Kun, Shi Mengdong, Fu Cong, and Huo Ran. Congenital cutis laxa: a case report and literature review. Frontiers in Surgery, Mar 2022. URL: https://doi.org/10.3389/fsurg.2022.814897, doi:10.3389/fsurg.2022.814897. This article has 10 citations.

8. (kun2022congenitalcutislaxa pages 1-2): Yang Kun, Shi Mengdong, Fu Cong, and Huo Ran. Congenital cutis laxa: a case report and literature review. Frontiers in Surgery, Mar 2022. URL: https://doi.org/10.3389/fsurg.2022.814897, doi:10.3389/fsurg.2022.814897. This article has 10 citations.

9. (graul‐neumann2008highlyvariablecutis pages 1-2): Luitgard M. Graul‐Neumann, Ingrid Hausser, Maximilian Essayie, Anita Rauch, and Cornelia Kraus. Highly variable cutis laxa resulting from a dominant splicing mutation of the elastin gene. American Journal of Medical Genetics Part A, 146A:977-983, Apr 2008. URL: https://doi.org/10.1002/ajmg.a.32242, doi:10.1002/ajmg.a.32242. This article has 92 citations.

10. (callewaert2011newinsightsinto pages 6-7): Bert Callewaert, Marjolijn Renard, Vishwanathan Hucthagowder, Beate Albrecht, Ingrid Hausser, Edward Blair, Cristina Dias, Alice Albino, Hiroshi Wachi, Fumiaki Sato, Robert P. Mecham, Bart Loeys, Paul J. Coucke, Anne De Paepe, and Zsolt Urban. New insights into the pathogenesis of autosomal‐dominant cutis laxa with report of five eln mutations. Human Mutation, 32:445-455, Apr 2011. URL: https://doi.org/10.1002/humu.21462, doi:10.1002/humu.21462. This article has 179 citations and is from a domain leading peer-reviewed journal.

11. (lasio2018elastindrivengeneticdiseases pages 4-6): Maria Laura Duque Lasio and Beth A. Kozel. Elastin-driven genetic diseases. Oct 2018. URL: https://doi.org/10.1016/j.matbio.2018.02.021, doi:10.1016/j.matbio.2018.02.021. This article has 122 citations and is from a domain leading peer-reviewed journal.

12. (okuneva2019anovelelastin pages 2-4): E. G. Okuneva, A. A. Kozina, N. V. Baryshnikova, A. Yu Krasnenko, K. Yu Tsukanov, O. I. Klimchuk, E. I. Surkova, and V. V. Ilinsky. A novel elastin gene frameshift mutation in a russian family with cutis laxa: a case report. BMC Dermatology, Jan 2019. URL: https://doi.org/10.1186/s12895-019-0084-6, doi:10.1186/s12895-019-0084-6. This article has 10 citations and is from a peer-reviewed journal.

13. (hadjrabia2013twentypatientsincluding pages 2-4): Smail Hadj-Rabia, Bert L Callewaert, Emmanuelle Bourrat, Marlies Kempers, Astrid S Plomp, Valerie Layet, Deborah Bartholdi, Marjolijn Renard, Julie De Backer, Fransiska Malfait, Olivier M Vanakker, Paul J Coucke, Anne M De Paepe, and Christine Bodemer. Twenty patients including 7 probands with autosomal dominant cutis laxa confirm clinical and molecular homogeneity. Orphanet Journal of Rare Diseases, 8:36-36, Feb 2013. URL: https://doi.org/10.1186/1750-1172-8-36, doi:10.1186/1750-1172-8-36. This article has 59 citations and is from a peer-reviewed journal.

14. (callewaert2011newinsightsinto pages 7-9): Bert Callewaert, Marjolijn Renard, Vishwanathan Hucthagowder, Beate Albrecht, Ingrid Hausser, Edward Blair, Cristina Dias, Alice Albino, Hiroshi Wachi, Fumiaki Sato, Robert P. Mecham, Bart Loeys, Paul J. Coucke, Anne De Paepe, and Zsolt Urban. New insights into the pathogenesis of autosomal‐dominant cutis laxa with report of five eln mutations. Human Mutation, 32:445-455, Apr 2011. URL: https://doi.org/10.1002/humu.21462, doi:10.1002/humu.21462. This article has 179 citations and is from a domain leading peer-reviewed journal.

15. (akcay2020consequencesofelastin pages 1-3): S Akcay. Consequences of elastin gene mutations in autosomal dominant cutis laxa and supravalvular aortic stenosis. Unknown journal, 2020.

16. (akcay2020consequencesofelastinb pages 1-3): S Akcay. Consequences of elastin gene mutations in autosomal dominant cutis laxa and supravalvular aortic stenosis. Unknown journal, 2020.

17. (merla2012supravalvularaorticstenosis pages 2-3): Giuseppe Merla, Nicola Brunetti-Pierri, Pasquale Piccolo, Lucia Micale, and Maria Nicla Loviglio. Supravalvular aortic stenosis: elastin arteriopathy. Circulation: Cardiovascular Genetics, 5:692–696, Dec 2012. URL: https://doi.org/10.1161/circgenetics.112.962860, doi:10.1161/circgenetics.112.962860. This article has 144 citations.

18. (akcay2020consequencesofelastina pages 1-3): S Akcay. Consequences of elastin gene mutations in autosomal dominant cutis laxa and supravalvular aortic stenosis. Unknown journal, 2020.

## Artifacts

- [Edison artifact artifact-00](Autosomal_Dominant_Cutis_Laxa_1-deep-research-falcon_artifacts/artifact-00.md)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 8 |
| Resolved | 8 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 8 |
| On topic | 2 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

No ontology term identifiers were found in this report.